Aprepitant Intravenous and Liver disease
Result of checking the interaction of drug Aprepitant Intravenous and disease Liver disease for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Aprepitant is primarily metabolized by the liver. In studies of patients with mild to moderate hepatic impairment (Child-Pugh score 5 to 9), aprepitant was well tolerated and no clinically significant alterations in its pharmacokinetics were observed. Thus, no dosage adjustment of aprepitant is necessary in this patient population. However, there are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh score > 9), and caution is advised if aprepitant is used in such patients.
- "Product Information. Emend (aprepitant)." Merck & Company Inc, West Point, PA.
Generic Name: aprepitant
Brand Name: Cinvanti, Emend, Emend 3-Day, Emend 2-Day
Synonyms: Aprepitant